Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229236 | 0.94 | LMNA (0.55) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL25660826 | 0.94 | LMNA (0.55) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4841513 | 0.86 | L3MBTL1 (0.65) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL30427490 | 0.85 | LMNA (0.56) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL25660825 | 0.85 | LMNA (0.56) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL18648449 | 0.85 | MAOB (0.54) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4840511 | 0.84 | L3MBTL1 (0.65) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4833423 | 0.80 | L3MBTL1 (0.53) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL5191638 | 0.79 | TDP1 (0.45) | L3MBTL1MAPTKMT2A | |
| SCHEMBL5194512 | 0.79 | ALDH1A1 (0.46) | L3MBTL1MAPTHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | L3MBTL1 1493/4885MAPT 763/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.